A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions

DRUG: Eribulin
DRUG: Adriamycin
DRUG: Cyclophosphamide

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]